Biologicals/biosimilar approved in EU and marketed in SI

Biosimilars approved in the EU published at EMA website – LINK

By clicking on an individual drug, the following information is displayed: overview about the drug in English and Slovenian, authorization details in English, Summary of the main characteristics of the drug – SmPC – in Slovenian and English, Assessment history (EPAR) in English.

Information on the current status of the drug’s presence on the Slovenian market is available on the website of the central drug database: Central drug database 2 – Search (cbz.si)

Reference:

Soliris

Biosimilar:

Bekemv

Reference:

Eprex

Biosimilars:

Abseamed

Binocrit

Retacrit

Others:

Eporatio  (epoetin theta)

NeoRecormon  (epoetin beta)

Reference:

Enbrel

Biosimilars:

Benepali

Erelzi

Reference:

Gonal-f

Biosimilars:

Bemfola

Ovaleap

Pergoveris

Puregon (follitropin beta)

Rekovelle (follitropin delta)

Actrapid

Insuman

Insulatard

Humulin M3

Humulin N

Humulin R

Mixtard

Reference:

Lucentis

Biosimilar:

Ximluci

Reference:

Forsteo

Biosimilars:

Movymia

Terrosa

Reference:

RoActemra

Biosimilar:

Tyenne

Reference:

Herceptin

Biosimilars:

Herzuma

Kanjinti

Ogivri

Ontruzant

Trazimera

Zercepac

Others:

Enhertu (trastuzumab deruxtecan)

Kadcyla (trastuzumab emtansine)

Phesgo (trastuzumab + pertuzumab)

Reference:

Stelara

Biosimilar:

Uzpruvo

Scroll to Top